The influence of drug-like concepts on decision-making in medicinal chemistry
The DOI matches its Crossref record; 59 of the 60 references it cites were found in a registry or an index.
Abstract
The application of guidelines linked to the concept of drug-likeness, such as the 'rule of five', has gained wide acceptance as an approach to reduce attrition in drug discovery and development. However, despite this acceptance, analysis of recent trends reveals that the physical properties of molecules that are currently being synthesized in leading drug discovery companies differ significantly from those of recently discovered oral drugs and compounds in clinical development. The consequences of the marked increase in lipophilicity--the most important drug-like physical property--include a greater likelihood of lack of selectivity and attrition in drug development. Tackling the threat of compound-related toxicological attrition needs to move to the mainstream of medicinal chemistry decision-making.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“(Note that liophilicity per se may not be relevant, as drugs require carriers to cross membranes [18], and promiscuity and off-target effects increase with lipophilicity [1679].)”
From Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases (2009) · cites this paper as [1679]
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
Molecular properties that influence the oral bioavailability of drug candidates
Veber, D. F., Johnson, S. R., Cheng, H.-Y., Smith, B. R., Ward, K. W., & Kopple, K. D. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020017n · Cited by 8,420 · cited 1×
“Overall oral bioavailability depends not just on absorption but also on dissolution, gut transit time and first-pass metabolism, so it is perhaps surprising that rat bioavailability can be categorized by simple physical properties such as PSA and rotatable bond”
BackgroundLead- and drug-like compounds: the rule-of-five revolution
Lipinski, C. A. (2004) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2004.11.007 · Cited by 6,199 · cited 1×
“jpg" NDATA ITEM> ]> Ten years have passed since the publication of the 'rule of five' physical property guidelines for drug permeabilit”
BackgroundCan the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Budavari, S. (1998) · Royal Society of Chemistry eBooks · Cited by 2,741
ADMET in silico modelling: towards prediction paradise?
van de Waterbeemd, H., & Gifford, E. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1032 · Cited by 1,863
Martin, Y. C. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0492002 · Cited by 1,020 · cited 1×
“, and number of rule-of-five violations, PSA and ionization stat”
BackgroundQuantitative approach to biochemical structure-activity relationships
Hansch, C. (1969) · Accounts of Chemical Research · doi:10.1021/ar50020a002 · Cited by 918 · cited 1×
“This is not surprising: the role of LogP in influencing drug potency, pharmacokinetics and toxicity has been established for many year”
BackgroundMolecular Complexity and Its Impact on the Probability of Finding Leads for Drug Discovery
Hann, M. M., Leach, A. R., & Harper, G. (2001) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci000403i · Cited by 877 · cited 1×
“This allows the processes of chemical optimization, which frequently increase physical propertie”
Background
Research works printed but not linked: 3
- Kubinyi, H. Lipophilicity and biological activity. Drug transport and drug distribution in model systems and in biological systems. Arzn. Forsch. 29, 1067–1080 (1979).
- Wood, A. Annual Reports in Medicinal Chemistry Volume 41 503–522 (Academic Press, Burlington, 2006).
- Gray, N. Changing Landscapes: A Special Report on the World's Top 50 Pharma Companies. Pharmaceutical Executive web site [online] , (2006)
Cited by
Items 301–400 of 1,006
Evaluation of blockbuster drugs under the Rule-of-five
Giménez, B. G., dos Santos, M. S., Ferrarini, M., Fernandes, J. P. S., & Fernandes, J. P. S. (2010) · Die Pharmazie · doi:10.31083/ph.2010.9733 · Cited by 106
The Time and Place for Nature in Drug Discovery
Young, R. J., Flitsch, S. L., Grigalunas, M., Leeson, P. D., Quinn, R. J., Turner, N. J., & Waldmann, H. (2022) · JACS Au · doi:10.1021/jacsau.2c00415 · Cited by 113
Self-citationLigand efficiency metrics in drug discovery: the pros and cons from a practical perspective
Cavalluzzi, M. M., Mangiatordi, G. F., Nicolotti, O., & Lentini, G. (2017) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2017.1365056 · Cited by 108
Rezki, N., Almehmadi, M. A., Ihmaid, S. K., Shehata, A. M., Omar, A. M., Ahmed, H. E. A., & Aouad, M. R. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.104133 · Cited by 104
Negatu, D. A., Gengenbacher, M., Dartois, V. A., & Dick, T. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.575586 · Cited by 119
Tzvetkov, N. T., Hinz, S., Küppers, P., Gastreich, M., & Müller, C. E. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500729a · Cited by 108
Pyrazole NNRTIs 4: Selection of UK-453,061 (lersivirine) as a Development Candidate
Mowbray, C. E., Burt, C., Corbau, R., Gayton, S., Hawes, M., Perros, M., Tran, I., Price, D. A., Quinton, F., Selby, M. D., et al. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.08.080 · Cited by 104
Sehgelmeble, F. W., Janson, J., Ray, C., Rosqvist, S., Gustavsson, S., Nilsson, L. I., Minidis, A. B. E., Holenz, J., Rotticci, D., Lundkvist, J., et al. (2012) · ChemMedChem · doi:10.1002/cmdc.201200014 · Cited by 113
Discovery of Small‐Molecule Interleukin‐2 Inhibitors from a DNA‐Encoded Chemical Library
Leimbacher, M., Zhang, Y., Mannocci, L., Stravs, M. A., Geppert, T., Scheuermann, J., Schneider, G., & Neri, D. (2012) · Chemistry - A European Journal · doi:10.1002/chem.201200952 · Cited by 103
“However, hit compounds isolated from such libraries are more likely to violate generally accepted criteria for lead-likeness, which in turn entails increased predicted risks of developability and their compatibility with chemical optimization procedures (Leeson and Springthorpe, 2007).”
BackgroundInfluentialNucleotide pyrophosphatase/phosphodiesterase 1 (NPP1) and its inhibitors
Lee, S.-Y., & Müller, C. E. (2017) · MedChemComm · doi:10.1039/c7md00015d · Cited by 109
Medicinal chemistry in drug discovery in big pharma: past, present and future
Campbell, I. B., Macdonald, S. J. F., & Procopiou, P. A. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.10.007 · Cited by 111
Nishiguchi, G., Keramatnia, F., Min, J., Chang, Y., Jonchere, B., Das, S., Actis, M., Price, J., Chepyala, D., Young, B., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01313 · Cited by 99
Fragment-to-Lead Medicinal Chemistry Publications in 2020
de Esch, I. J. P., Erlanson, D. A., Jahnke, W., Johnson, C. N., & Walsh, L. M. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01803 · Cited by 114
Natural products as lead structures: chemical transformations to create lead-like libraries
Pascolutti, M., & Quinn, R. J. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.10.013 · Cited by 104
Janga, S. C., & Tzakos, A. G. (2009) · Molecular BioSystems · doi:10.1039/b908147j · Cited by 110
Baragaña, B., Norcross, N. R., Wilson, C., Porzelle, A., Hallyburton, I., Grimaldi, R., Osuna‐Cabello, M., Norval, S., Riley, J., Stojanovski, L., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00723 · Cited by 102
“Early examples of substitution at R 3 showed that introduction of amines, such as dimethylamine ( 36 ) and morpholine ( 37 ), reduced lipophilicity and was tolerated in terms of potency compared to compounds 11 and 19 (Table 4).”
Advancing the Drug Discovery and Development Process
Nicolaou, K. C. (2014) · Angewandte Chemie · doi:10.1002/ange.201404761 · Cited by 101
Liang, J., van Abbema, A., Balázs, M., Barrett, K., Berezhkovsky, L., Blair, W., Chang, C. C., Delarosa, D., DeVoss, J., Driscoll, J., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400266t · Cited by 108
The thermodynamic basis for the use of lipophilic efficiency (LipE) in enthalpic optimizations
Shultz, M. D. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.08.030 · Cited by 105
Stepan, A. F., Kauffman, G. W., Keefer, C. E., Verhoest, P. R., & Edwards, M. P. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4008642 · Cited by 107
Betschart, C., Hintermann, S., Behnke, D., Cotesta, S., Fendt, M., Gee, C. E., Jacobson, L. H., Laue, G., Ofner, S., Chaudhari, V. D., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4007627 · Cited by 105
Synergistic potential of Citrus aurantium L. essential oil with antibiotics against Candida albicans
Nidhi, P., Rolta, R., Kumar, V., Dev, K., & Sourirajan, A. (2020) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2020.113135 · Cited by 111
Sykes, D. A., Parry, C., Reilly, J., Wright, P., Fairhurst, R. A., & Charlton, S. J. (2014) · Molecular Pharmacology · doi:10.1124/mol.113.090209 · Cited by 113
“It should be noted that this term is similar to lipophilic efficiency, which is used as a practical way of assessing the drug-like qualities of a compound (Leeson and Springthorpe, 2007).”
BackgroundClemons, P. A., Wilson, J. A., Dančík, V., Muller, S., Carrinski, H. A., Wagner, B. K., Koehler, A. N., & Schreiber, S. L. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1015024108 · Cited by 101
Increasing small molecule drug developability in sub-optimal chemical space
Ritchie, T. J., Macdonald, S. J. F., Peace, S., Pickett, S. D., & Luscombe, C. N. (2013) · MedChemComm · doi:10.1039/c3md00003f · Cited by 100
Discovery of cell-active phenyl-imidazole Pin1 inhibitors by structure-guided fragment evolution
Potter, A. J., Oldfield, V., Nunns, C. L., Fromont, C., Ray, S. C., Northfield, C. J., Bryant, C., Scrace, S., Robinson, D. A., Matossova, N., et al. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.09.063 · Cited by 99
Similarity methods in chemoinformatics
Willett, P. (2009) · Annual Review of Information Science and Technology · doi:10.1002/aris.2009.1440430108 · Cited by 112
Privileged scaffolds in lead generation
Zhao, H., & Dietrich, J. D. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1041496 · Cited by 110
“The younger generation of medicinal chemists is more familiar with using Lipinski’s rule-of-five and related principles to eliminate active compounds with less desirable physiochemical properties [57].”
MethodDoyle, K. J., Lönn, H., Käck, H., de Poël, A. J. V., Swallow, S., Gardiner, P., Connolly, S., Root, J. A., Wikell, C., Dahl, G., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01127 · Cited by 98
Xanthones, A Promising Anti-Inflammatory Scaffold: Structure, Activity, and Drug Likeness Analysis
Feng, Z., Lu, X., Gan, L., Zhang, Q., & Lin, L. (2020) · Molecules · doi:10.3390/molecules25030598 · Cited by 101
“The major role of lipophilicity in drug discovery is to balance potency and ADME properties [79].”
BackgroundTools for Early Prediction of Drug Loading in Lipid-Based Formulations
Alskär, L. C., Porter, C. J. H., & Bergström, C. A. S. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00704 · Cited by 94
Pasquier, B., El‐Ahmad, Y., Filoche-Rommé, B., Dureuil, C., Fassy, F., Abécassis, P.-Y., Mathieu, M., Bertrand, T., Bénard, T., Barrière, C., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5013352 · Cited by 106
Ranković, Z. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01469 · Cited by 102
RetractedKawai, J., Toki, T., Ota, M., Inoue, H., Takata, Y., Asahi, T., Suzuki, M., Shimada, T., Ono, K., Suzuki, K., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01113 · Cited by 94
Advancing the Drug Discovery and Development Process
Nicolaou, K. C. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201404761 · Cited by 88
Gad, E. M., Nafie, M. S., Eltamany, E. H. M., Hammad, M. S. A. G., Barakat, A., & Boraei, A. T. A. (2020) · Molecules · doi:10.3390/molecules25112523 · Cited by 93
Wang, C. K. L., Northfield, S. E., Swedberg, J. E., Colless, B., Chaousis, S., Price, D. A., Liras, S. I., & Craik, D. J. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.04.049 · Cited by 97
Lipid Bilayer–mediated Regulation of Ion Channel Function by Amphiphilic Drugs
Lundbæk, J. A. (2008) · The Journal of General Physiology · doi:10.1085/jgp.200709948 · Cited by 93
“” ( Leeson and Springthorpe, 2007 ). The use of gA-based measurements of drug-induced changes in bilayer stiffness, or test of whether the effects of a drug can be reproduced by a structurally different compound known to alter bilayer stiffness (e.g., Triton X; Matta et al., 2007), may provide suitable tools in this e…”
BackgroundInfluential(Q)SAR Modeling and Safety Assessment in Regulatory Review
Kruhlak, N. L., Benz, R. D., Zhou, H., & Colatsky, T. J. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.300 · Cited by 92
Properties of FDA-approved small molecule protein kinase inhibitors: A 2025 update
Roskoski, R. J. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107723 · Cited by 109
Dangol, M., Yang, H., Li, C. G., Lahiji, S. F., Kim, S., Ma, Y., & Jung, H. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.12.038 · Cited by 91
The Need for Restructuring the Disordered Science of Amorphous Drug Formulations
Edueng, K., Mahlin, D., & Bergström, C. A. S. (2017) · Pharmaceutical Research · doi:10.1007/s11095-017-2174-7 · Cited by 110
Nunes, A. M. V., de Andrade, F. D. C. P., Filgueiras, L. A., Maia, O. A. D. C., Cunha, R. L. O. R., Rodezno, S. V. A., Filho, A. L. M. M., Carvalho, F. A. D. A., Bráz, D. C., & Mendes, A. N. (2020) · Environmental Toxicology and Pharmacology · doi:10.1016/j.etap.2020.103470 · Cited by 90
Opportunities and Challenges for Fatty Acid Mimetics in Drug Discovery
Proschak, E., Heitel, P., Kalinowsky, L., & Merk, D. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01287 · Cited by 95
Proline-Based Allosteric Inhibitors of Zika and Dengue Virus NS2B/NS3 Proteases
Millies, B., von Hammerstein, F., Gellert, A., Hammerschmidt, S., Barthels, F., Göppel, U., Immerheiser, M., Elgner, F., Jung, N., Basic, M., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01697 · Cited by 89
Therapeutics—how to treat phase separation-associated diseases
Wheeler, R. J. (2020) · Emerging Topics in Life Sciences · doi:10.1042/etls20190176 · Cited by 98
Dark Classics in Chemical Neuroscience: Δ9-Tetrahydrocannabinol
Banister, S. D., Arnold, J. C., Connor, M., Glass, M., & McGregor, I. S. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00651 · Cited by 86
Colomer, I., Empson, C. J., Craven, P. G. E., Owen, Z., Doveston, R. G., Churcher, I., Marsden, S. P., & Nelson, A. S. (2016) · Chemical Communications · doi:10.1039/c6cc03244c · Cited by 88
6-Amino-3-methylpyrimidinones as Potent, Selective, and Orally Efficacious SHP2 Inhibitors
Sarver, P., Acker, M., Bagdanoff, J. T., Chen, Z., Chen, Y.-N., Chan, H., Firestone, B., Fodor, M., Fortanet, J., Hao, H., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01726 · Cited by 87
Patel, S. D., Cohen, F., Dean, B. J., Torre, K. D. L., Deshmukh, G. S., Estrada, A. A., Ghosh, A. S., Gibbons, P., Gustafson, A. E., Huestis, M. P., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5013984 · Cited by 95
Warner, D. J., Chen, H., Cantin, L., Kenna, J. G., Stahl, S. H., Walker, C., & Noeske, T. (2012) · Drug Metabolism and Disposition · doi:10.1124/dmd.112.047068 · Cited by 93
“How lipophilicity and molecular weight might relate to toxicity or adverse events has been reported earlier (Leeson and Springthorpe, 2007), although the precise property ranges over which this relationship takes hold are surprising.”
BackgroundAromatic chloride to nitrile transformation: medicinal and synthetic chemistry
Jones, L. H., Summerhill, N. W., Swain, N. A., & Mills, J. E. J. (2010) · MedChemComm · doi:10.1039/c0md00135j · Cited by 87
Skerratt, S. E., Andrews, M. D., Bagal, S. K., Bilsland, J., Brown, D., Bungay, P. J., Cole, S. M., Gibson, K. R., Jones, R., Morao, I., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00850 · Cited by 89
Meanwell, N. A. (2013) · Topics in medicinal chemistry · doi:10.1007/7355_2013_29 · Cited by 100
Recent progress on nuclear receptor RORγ modulators
Cyr, P., Bronner, S. M., & Crawford, J. J. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.08.012 · Cited by 90
Impact of ion class and time on oral drug molecular properties
Leeson, P. D., St-Gallay, S. A., & Wenlock, M. C. (2010) · MedChemComm · doi:10.1039/c0md00157k · Cited by 87
Self-citationReducing the Risk of Drug Attrition Associated with Physicochemical Properties
Leeson, P. D., & Empfield, J. R. (2010) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(10)45024-1 · Cited by 85
Self-citationCheminformatic Tools for Medicinal Chemists
Muchmore, S. W., Edmunds, J. J., Stewart, K. D., & Hajduk, P. J. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100164z · Cited by 85
Cid, J. M., Tresadern, G., Vega, J. A., de Lucas, A. I., Matesanz, E., Iturrino, L., Linares, M. L., Molina, A. G., Andrés, J. I., Macdonald, G. J., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3010724 · Cited by 93
HTS and hit finding in academia – from chemical genomics to drug discovery
Frearson, J. A., & Collie, I. T. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.09.004 · Cited by 91
“In addition, libraries intended for drug discovery utility need to further adhere to a restricted range of physicochemical properties necessary for both parenteral or oral bioavailability and, perhaps, central nervous system penetration [23,24].”
BackgroundCan we discover pharmacological promiscuity early in the drug discovery process?
Peters, J., Hert, J., Bissantz, C., Hillebrecht, A., Gerebtzoff, G., Bendels, S., Tillier, F., Migeon, J., Fischer, H., Guba, W., et al. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.01.001 · Cited by 87
Design of Selective, ATP-Competitive Inhibitors of Akt
Freeman‐Cook, K. D., Autry, C. L., Borzillo, G. V., Gordon, D., Barbacci-Tobin, E. G., Bernardo, V., Briere, D. M., Clark, T. H., Corbett, M. S., Jakubczak, J. L., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm1003842 · Cited by 90
Nakano, H., Saito, N., Parker, L. J., Tada, Y., Abe, M., Tsuganezawa, K., Yokoyama, S., Tanaka, A., Kojima, H., Okabe, T., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3001289 · Cited by 84
O’ Donovan, D. H., De Fusco, C., Kuhnke, L., & Reichel, A. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01577 · Cited by 83
Minor Structural Change to Tertiary Sulfonamide RORc Ligands Led to Opposite Mechanisms of Action
René, O., Fauber, B. P., Boenig, G. D. L., Burton, B., Eidenschenk, C., Everett, C., Gobbi, A., Hymowitz, S. G., Johnson, A. R., Kiefer, J. R., et al. (2014) · ACS Medicinal Chemistry Letters · doi:10.1021/ml500420y · Cited by 89
Lanthaler, K., Bilsland, E., Dobson, P. D., Moss, H. J., Pir, P., Kell, D. B., & Oliver, S. G. (2011) · BMC Biology · doi:10.1186/1741-7007-9-70 · Cited by 84
“Of the many reasons for the attrition of candidate drugs during the development process, toxicity or lack of efficacy in vivo are among the most frequent [1,2].”
BackgroundCarboxylic Acid Bioisosteres in Medicinal Chemistry: Synthesis and Properties
Bredael, K., Geurs, S., Clarisse, D., Bosscher, K. D., & D’hooghe, M. (2022) · Journal of Chemistry · doi:10.1155/2022/2164558 · Cited by 97
Bajorath, J. (2015) · F1000Research · doi:10.12688/f1000research.6653.1 · Cited by 80
Development of Autotaxin Inhibitors: An Overview of the Patent and Primary Literature
Castagna, D., Budd, D. C., Macdonald, S. J. F., Jamieson, C., & Watson, A. J. B. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01599 · Cited by 88
Šink, R., Sosič, I., Živec, M., Fernandez-Menendez, R., Turk, S., Pajk, S., Álvarez-Gómez, D., López-Román, E. M., González‐Cortés, C., Rullas-Triconado, J., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501029r · Cited by 81
Copper-Catalyzed Aerobic Oxidative Intramolecular Alkene C–H Amination Leading to N-Heterocycles
Lu, J., Jin, Y., Liu, H., Jiang, Y., & Fu, H. (2011) · Organic Letters · doi:10.1021/ol2013395 · Cited by 81
The CSD Drug Subset: The Changing Chemistry and Crystallography of Small Molecule Pharmaceuticals
Bryant, M. J., Black, S. N., Blade, H., Docherty, R., Maloney, A. G. P., & Taylor, S. C. (2019) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2018.12.011 · Cited by 83
Targeting G-quadruplex nucleic acids with heterocyclic alkaloids and their derivatives
Xiong, Y., Huang, Z., & Tan, J. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.11.021 · Cited by 82
What does the aromatic ring number mean for drug design?
Ward, S. E., & Beswick, P. (2014) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2014.932346 · Cited by 84
“Medicinal chemists were preparing compounds in a different region of chemical space compared with previous generations, and modern compounds were generally more lipophilic, less polar and of higher molecular weight when compared with those from earlier decades [17].”
ResultImplications of the Dominant Role of Transporters in Drug Uptake by Cells (Supplementary Material)
Dobson, P. D., Lanthaler, K., Oliver, S. G., & Kell, D. B. (2009) · Current Topics in Medicinal Chemistry · doi:10.2174/156802609787521616 · Cited by 94
“Overall, many metabolites are quite hydrophilic, and a move towards hydrophilicity by coupling metabolite moieties to candidate drugs may considerably lower their promiscuity, as promiscuity correlates strongly with lipophilicity [124].”
BackgroundDiscovery of Selective LRRK2 Inhibitors Guided by Computational Analysis and Molecular Modeling
Chen, H., Chan, B. K., Drummond, J., Estrada, A. A., Gunzner, J. L., Liu, X., Liu, Y., Moffat, J. G., Shore, D. G., Sweeney, Z. K., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300452p · Cited by 84
Installing amino acids and peptides on N-heterocycles under visible-light assistance
Jin, Y., Jiang, M., Wang, H., & Fu, H. (2016) · Scientific Reports · doi:10.1038/srep20068 · Cited by 80
Strategies to apply 3Rs in preclinical testing
Gorzalczany, S. B., & Basso, A. (2021) · Pharmacology Research & Perspectives · doi:10.1002/prp2.863 · Cited by 91
The role of the methoxy group in approved drugs
Chiodi, D., & Ishihara, Y. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116364 · Cited by 85
Calderón, F., Barros, D., Bueno, J. M., Coterón, J. M., Fernández, E., Gamo, F., Lavandera, J. L., León, M. L., Macdonald, S. J. F., Mallo, A., et al. (2011) · ACS Medicinal Chemistry Letters · doi:10.1021/ml200135p · Cited by 80
Inflation of correlation in the pursuit of drug-likeness
Kenny, P. W., & Montanari, C. A. (2013) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-012-9631-5 · Cited by 81
“On this basis, it can be argued that the analysis presented in LS2007 [22] does not support the assertion of a dominant role for lipophilicity in promoting binding to unwanted drug targets.”
BackgroundMethodInfluentialInsights into Molecular Basis of Cytochrome P450 Inhibitory Promiscuity of Compounds
Cheng, F., Yu, Y., Zhou, Y., Shen, Z., Xiao, W. J., Liu, G., Li, W., Lee, P. W., & Tang, Y. (2011) · Journal of Chemical Information and Modeling · doi:10.1021/ci200317s · Cited by 87
Nuth, M., Guan, H., Zhukovskaya, N. L., Saw, Y. L., & Ricciardi, R. P. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301735k · Cited by 80
McCoull, W., Abrams, R. D., Anderson, E., Blades, K., Barton, P., Box, M., Burgess, J., Byth, K., Cao, Q., Chuaqui, C., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00359 · Cited by 76
“67 nM His BCL6 (5-129) C8Q, C67R & C84N, 0.”
MethodInfluentialKlepsch, F., Chiba, P., & Ecker, G. F. (2011) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002036 · Cited by 80
“As high lipophilicity correlates with promiscuity, poor solubility and poor metabolic clearance [38], candidates with high lipophilic efficiency (LLE = log(potency) - logP) are preferred.”
BackgroundDockey: a modern integrated tool for large-scale molecular docking and virtual screening
Du, L., Geng, C., Zeng, Q., Huang, T. L., Tang, J., Chu, Y., & Zhao, K. (2023) · Briefings in Bioinformatics · doi:10.1093/bib/bbad047 · Cited by 87
García-Sosa, A. T. (2013) · Journal of Chemical Information and Modeling · doi:10.1021/ci3005786 · Cited by 81
Recent Advances in Physicochemical and ADMET Profiling in Drug Discovery
Wang, J., & Skolnik, S. M. (2009) · Chemistry & Biodiversity · doi:10.1002/cbdv.200900117 · Cited by 79
Nikolic, K. M., Mavridis, L., Djikić, T., Vučićević, J., Agbaba, D. D., Yelekçi, K., & Mitchell, J. B. O. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00265 · Cited by 83
“Higher lipophilicity causes low solubility, high plasma protein binding, and increased metabolic and toxicity risks in CNS drugs (Leeson and Springthorpe, 2007).”
BackgroundGulati, S., Jin, H., Masuho, I., Orban, T., Cai, Y., Pardon, E., Martemyanov, K. A., Kiser, P. D., Stewart, P. L., Ford, C., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04432-0 · Cited by 78
Discovery of Sisunatovir (RV521), an Inhibitor of Respiratory Syncytial Virus Fusion
Cockerill, G. S., Angell, R. M., Bedernjak, A. F., Chuckowree, I., Fraser, I. S., Gascon, J. M., Gilman, M. S. A., Good, J. A. D., Harland, R., Johnson, S. M., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01882 · Cited by 78
Preparation of Aryloxetanes and Arylazetidines by Use of an Alkyl−Aryl Suzuki Coupling
Duncton, M. A. J., Estiarte, M. A., Tan, D. Q., Kaub, C. J., O’Mahony, D. J. R., Johnson, R. J. K., Cox, M. O., Edwards, W. T., Wan, M., Kincaid, J., et al. (2008) · Organic Letters · doi:10.1021/ol8011327 · Cited by 78
Chatterjee, J., Rechenmacher, F., & Kessler, H. (2012) · Angewandte Chemie · doi:10.1002/ange.201205674 · Cited by 79
Xu, H., & Fu, H. (2011) · Chemistry - A European Journal · doi:10.1002/chem.201102794 · Cited by 78
Grime, K., Barton, P., & McGinnity, D. F. (2012) · Molecular Pharmaceutics · doi:10.1021/mp300476z · Cited by 81
Reis, J., Cagide, F., Estrada, M., Teixeira, J., Bagetta, D., Pérez, C., Uriarte, E., Oliveira, P. J., Ortuso, F., Alcaro, S., et al. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.07.056 · Cited by 78
Fragment-to-Lead Medicinal Chemistry Publications in 2018
Erlanson, D. A., de Esch, I. J. P., Jahnke, W., Johnson, C. N., & Mortenson, P. N. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01581 · Cited by 80
Gonçalves, V., Brannigan, J. A., Whalley, D. P., Ansell, K. H., SAXTY, B. A., Holder, A. A., Wilkinson, A. J., Tate, E. W., & Leatherbarrow, R. J. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300040p · Cited by 77
“7 A number of potential substrates were tested, with Homo sapiens pp60 src (2-16) (GSNKSKPKDASQRRR-NH2) being chosen as the most suitable substrate for the PvNMT assay, with apparent Km (Km app ) of 5.”
MethodScott, J. S., Birch, A. M., Brocklehurst, K. J., Broo, A., Brown, H. S., Butlin, R. J., Clarke, D. S., Davidsson, Ö., Ertan, A., Goldberg, K., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300310c · Cited by 77
Ju, H., Zhang, J., Huang, B., Kang, D., Huang, B., Liu, X., & Zhan, P. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01227 · Cited by 80
Metadata
- Authors
- Leeson, P. D., & Springthorpe, B.
- Affiliations
- AstraZeneca (United Kingdom) (GB)
- Corresponding author
- Leeson, Paul D.
- ORCID
- Leeson, Paul D.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2007-11
- Volume
- 6
- Issue
- 11
- Pages
- 881-890
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2062458432
- Cited by
- 2,403
- References
- 60
- Citations by year
- 2026: 143 · 2025: 113 · 2024: 140 · 2023: 127 · 2022: 104 · 2021: 144 · 2020: 105 · 2019: 146 · 2018: 119 · 2017: 140 · 2016: 145 · 2015: 140 · 2014: 151 · 2013: 160 · 2012: 165
- FWCI
- 6.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- AstraZeneca
- Merck
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Keywords
- drug-likeness, Lipinski's rule of five, lipophilicity, drug attrition, drug discovery, drug selectivity
- MeSH terms
- Chemistry, Pharmaceutical, Decision Making, Pharmaceutical Preparations, Humans, Water, 1-Octanol
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.